Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors
| Autor: | Timofey D. Lebedev, Elmira R. Khabusheva, Sofia R. Mareeva, Karina A. Ivanenko, Alexey V. Morozov, Pavel V. Spirin, Petr M. Rubtsov, Anastasiya V. Snezhkina, Anna V. Kudryavtseva, Maxim I. Sorokin, Anton A. Buzdin, Vladimir S. Prassolov |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Mitogen-Activated Protein Kinase Kinases
Proto-Oncogene Proteins B-raf Indazoles Cell Survival MAP Kinase Signaling System Pyridones Diphenylamine Aminopyridines Antineoplastic Agents Cell Biology Biochemistry Piperazines Proto-Oncogene Proteins p21(ras) Neuroblastoma Pyrimidines Cell Line Tumor Benzamides Humans Pyrazoles Pyrroles Molecular Biology Protein Kinase Inhibitors |
| Zdroj: | The Journal of biological chemistry. 298(8) |
| ISSN: | 1083-351X |
| Popis: | Increased MAPK signaling is a hallmark of various cancers and is a central regulator of cell survival. Direct ERK1/2 inhibition is considered a promising approach to avoid ERK1/2 reactivation caused by upstream kinases BRAF, MEK1/2, and KRAS, as well as by receptor tyrosine kinase inhibitors, but the dynamics and selectivity of ERK1/2 inhibitors are much less studied compared with BRAF or MEK inhibitors. Using ERK1/2 and downstream kinase ELK1 reporter cell lines of lung cancer (H1299; NRAS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|